PubMed

Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women.

Schousboe JT, Nyman JA, Kane RL, Ensrud KE.

Ann Intern Med. 2005 May 3;142(9):734-41.PMID: 15867405 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score>-2.5 for alendronate therapy: a modeling study.

Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton LJ 3rd.

J Clin Densitom. 2006 Apr-Jun;9(2):133-43. Epub 2006 Apr 18.PMID: 16785071 [PubMed - indexed for MEDLINE]Related articles

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.

Health Technol Assess. 2005 Jun;9(22):1-160. Review.PMID: 15929857 [PubMed - indexed for MEDLINE]Related articlesFree article

Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy.

Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton LJ 3rd.

Osteoporos Int. 2005 Dec;16(12):1883-93. Epub 2005 Aug 31.PMID: 16133649 [PubMed - indexed for MEDLINE]Related articles

Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.

Schousboe JT, Ensrud KE, Nyman JA, Melton LJ 3rd, Kane RL.

J Am Geriatr Soc. 2005 Oct;53(10):1697-704.PMID: 16181168 [PubMed - indexed for MEDLINE]Related articles

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.PMID: 15575171 [PubMed - indexed for MEDLINE]Related articles

Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy.

Schousboe JT, Bauer DC, Nyman JA, Kane RL, Melton LJ, Ensrud KE.

Osteoporos Int. 2007 Feb;18(2):201-10. Epub 2006 Sep 20.PMID: 17019515 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.

Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, Melton LJ 3rd, Bauer DC, Ensrud KE.

JAMA. 2007 Aug 8;298(6):629-37.PMID: 17684185 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia.

Meadows ES, Klein R, Rousculp MD, Smolen L, Ohsfeldt RL, Johnston JA.

BMC Womens Health. 2007 Apr 17;7:6.PMID: 17439652 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.

Johnell O, Jönsson B, Jönsson L, Black D.

Pharmacoeconomics. 2003;21(5):305-14.PMID: 12627984 [PubMed - indexed for MEDLINE]Related articles

The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.

Stevenson M, Davis S, Lloyd-Jones M, Beverley C.

Health Technol Assess. 2007 Feb;11(4):1-134. Review.PMID: 17280622 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.

Ström O, Borgström F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA.

Osteoporos Int. 2007 Aug;18(8):1047-61. Epub 2007 Feb 28.PMID: 17333449 [PubMed - indexed for MEDLINE]Related articles

Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.

Tosteson AN, Burge RT, Marshall DA, Lindsay R.

Am J Manag Care. 2008 Sep;14(9):605-15.PMID: 18778176 [PubMed - indexed for MEDLINE]Related articlesFree article

Summaries for patients. Cost-effectiveness of alendronate in postmenopausal women with low bone mass without osteoporosis or previous fracture.

[No authors listed]

Ann Intern Med. 2005 May 3;142(9):I36. No abstract available. PMID: 15867399 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.

Borgström F, Johnell O, Jönsson B, Zethraeus N, Sen SS.

Bone. 2004 Jun;34(6):1064-71.PMID: 15193554 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.

Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H.

Curr Med Res Opin. 2007 Oct;23(10):2517-29.PMID: 17825128 [PubMed - indexed for MEDLINE]Related articles

A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.

Buckley LM, Hillner BE.

J Rheumatol. 2003 Jan;30(1):132-8.PMID: 12508402 [PubMed - indexed for MEDLINE]Related articles

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.

Arch Intern Med. 1997 Dec 8-22;157(22):2617-24.PMID: 9531231 [PubMed - indexed for MEDLINE]Related articles

The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.

Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM.

Arch Intern Med. 2006 Jun 12;166(11):1209-17.PMID: 16772249 [PubMed - indexed for MEDLINE]Related articlesFree article

Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy.

Mullins CD, Ohsfeldt RL.

J Manag Care Pharm. 2003 Mar-Apr;9(2):150-8.PMID: 14613344 [PubMed - indexed for MEDLINE]Related articlesFree article